Zylt pills 75mg №14

Active ingredient and dosage form

Zylt - coated tablets:

1 tab. contains Clopidogrel (in the form of hydrogensulfate) 75 mg; 14, 28, 30, 56, 84 or 90 pieces per pack.

Mechanism of action

Zylt - antiplatelet. Clopidogrel prevents the binding of adenosine phosphate (ADP) to the receptors located on the surface of platelets, and the activation of GP IIb / IIIa complex. This leads to inhibition of ADP-dependent platelet aggregation. It also leads to inhibition of platelet aggregation under the influence of other stimuli; the effect of ADP produced in each activated platelet is reduced, and the aggregation of the remaining platelets is stimulated. The effect of clopidogrel lasts throughout the life of the platelet, the platelet function is restored 7-10 days after discontinuation of clopidogrel.

Indications and usage

Prevention of ischemic disorders (myocardial infarction, stroke, thrombosis of peripheral arteries, sudden vascular death) in patients with atherosclerosis, including after myocardial infarction (up to 35 days), ischemic stroke (from 7 days to 6 months) or against the background of diagnosed occlusive peripheral arterial diseases.

Contraindications

hypersensitivity to clopidogrel and / or any of the components of Zilt;

severe liver failure;

hemorrhagic syndrome, acute bleeding (includingintracranial hemorrhage) and diseases predisposing to its development (gastric ulcer and duodenal ulcer in the acute stage, ulcerative colitis, tuberculosis, lung tumors, hyperfibrinolysis);

pregnancy;

lactation period;

age up to 18 years.

Adverse reactions

Adverse events rarely require discontinuation of treatment with clopidogrel.

General: chest pain, trauma, flu-like symptoms, pain, fatigue, asthenia, hernia.

Central and peripheral nervous system: headache, dizziness, paresthesia, leg cramps, hyperesthesia, neuralgia.

Vegetative nervous system: syncope, palpitations.

Cardiovascular system: peripheral edema, arterial hypertension, heart failure, generalized edema.

Gastrointestinal tract: abdominal pain, dyspepsia, diarrhea, nausea, constipation, vomiting, taste disturbances, perforation of gastric ulcers, hemorrhagic gastritis, bleeding from ulcers of the upper GI tract.

Liver and biliary tract: increased activity of liver enzymes, hyperbilirubinemia, hepatitis, liver steatosis.

Blood and blood-forming organs: thrombocytopenia, anemia (aplastic or hypochromic), agranulocytosis, leukopenia, neutropenia.

Coagulation disorders and bleeding: purpura, extravasation, epistaxis, Gastrointestinal bleeding, hemorrhages in the joints, hemorrhages from the urinary tract, hemoptysis, intracranial hemorrhages, retroperitoneal hemorrhages,bleeding from postoperative wounds, eye hemorrhages, hemothorax, pulmonary hemorrhages, allergic purpura, thrombotic thrombocytopenic purpura.

Musculoskeletal system: arthralgia, back pain, arthritis, arthrosis.

Dosage and Administration

The drug should be taken orally, regardless of the meal. The recommended dose of Zilta for adults (including elderly patients) is 75 mg / day (table 1).

Special notes

In patients with myocardial infarction, Zylt treatment should not begin in the first few days after a heart attack. Clopidogrel prolongs bleeding time. Zilt should be administered with caution to patients with an increased risk of bleeding after injuries, operations or as a result of other pathological conditions, as well as patients with a tendency to bleeding (especially gastrointestinal and intraocular hemorrhages). Clopidogrel treatment should be discontinued at least 7 days before the planned surgical intervention (including dental procedures).

Storage conditions

The drug should be stored in a dry, dark place at temperatures not above 20 ° C.